Dariohealth Corp Stock Price, News & Analysis

DarioHealth (NASDAQ: DRIO), a global digital health market leader, has announced a $17.5 million private placement of common stock. The company will sell 2,713,180 shares at $6.45 per share, with the offering expected to close around September 23, 2025.

The private placement is being conducted under Section 4(a)(2) of the Securities Act and Regulation D, with the company committing to file a registration statement with the SEC for the resale of the shares. The proceeds will be used for general corporate purposes.

DarioHealth (NASDAQ: DRIO) released a shareholder update highlighting its strategic progress in the digital health market. The company's multi-condition platform addresses 5 chronic conditions including diabetes, hypertension, weight management, musculoskeletal, and behavioral health on a unified platform.

The company reported a commercial pipeline worth $67 million, supported by partnerships with TPAs and pharmacy managers representing 87 million member lives. Clinical studies demonstrate significant outcomes, including $5,000 annual payer savings per user, 23% reduction in hospitalizations, and 9% reduction in healthcare utilization.

DarioHealth (NASDAQ: DRIO) announced the successful launch of five new employer contracts, including its largest employer contract to date, covering 107,000 lives. The contracts, implemented during Q2 and Q3 2025, feature Dario's complete cardiometabolic suite.

The company's digital health solutions have demonstrated significant results: 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user. Clinical outcomes include a 1.4% reduction in eHbA1c for diabetes, 10% reduction in BMI for prediabetes, and 38% of users reducing blood pressure by one stage.

Dario maintains a robust pipeline of $67 million in commercial opportunities and targets approximately 40 new client signings by year-end 2025, representing a 35% increase over 2024.

DarioHealth (NASDAQ: DRIO), a digital health market leader, has announced a 20-for-1 reverse stock split effective August 28, 2025. The company's outstanding common stock will be reduced from 47,996,572 to approximately 2,399,829 shares.

The split was approved by DRIO's board of directors following stockholder authorization at the July 23, 2025 Annual Meeting. Trading will continue under the "DRIO" symbol but with a new CUSIP Number (23725P 308). The company's authorized shares remain at 400,000,000, and fractional shares will be rounded up to the nearest whole share per stockholder.

The reverse split will not materially affect stockholders' ownership percentages or voting power, and all options, convertible securities, restricted stocks, and warrants will be appropriately adjusted.

DarioHealth (NASDAQ: DRIO) reported Q2 2025 financial results with revenue of $5.4 million, down from $6.3 million in Q2 2024 and $6.8 million in Q1 2025. Despite the revenue decline, the company showed significant operational improvements with a 43% reduction in operating loss and a 36% decrease in operating expenses year-over-year.

The company secured 21 new clients year-to-date and reported approximately $5 million in new committed annual recurring revenues (CARR), with a robust pipeline of $53 million in commercial opportunities. Gross margin improved to 55% compared to 44% in Q2 2024, with B2B2C operations maintaining approximately 80% non-GAAP gross margins.

Due to implementation delays, Dario has adjusted its cashflow breakeven timeline by 12-15 months, now expected between late 2026 and early 2027.

DarioHealth (Nasdaq: DRIO), a leader in the global digital health market, will release its Q2 2025 financial results on Tuesday, August 12th, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time, before market opens.

The earnings call will be hosted by CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda. Participants can join via dial-in numbers or through the Call me™ link, which will be active 15 minutes before the call. A replay will be available until August 26th, 2025.

DarioHealth (NASDAQ: DRIO) has announced a strategic commercial agreement with GreenKey Health to address the $150 billion sleep apnea market. The collaboration combines Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach to obstructive sleep apnea (OSA) management.

The partnership targets 29 million Americans affected by sleep apnea, with up to 80% of moderate to severe cases currently undiagnosed. The joint solution aims to improve member outcomes, reduce healthcare costs, and increase productivity through integrated behavioral health, sleep, and cardiometabolic care. The initiative will focus on engaging Commercial, ASO, Medicaid, Medicare Advantage plans, self-funded employers, and other healthcare stakeholders.

DarioHealth (NASDAQ: DRIO) presented four groundbreaking studies at the 85th Annual American Diabetes Association Scientific Sessions, showcasing significant achievements in GLP-1 medication management and AI-powered personalization.

A landmark study of 715 GLP-1 users demonstrated remarkable improvements, with average blood glucose dropping from eA1c of 9.0% to 6.7%. Notably, patients maintained stable outcomes for six months after discontinuing GLP-1 medication, showing no significant weight or glucose rebound.

The company's AI research achieved 89% accuracy in predicting next-month blood glucose levels using machine learning models. The studies revealed that the first four months of engagement are crucial for personalized care, with older adults (60+) showing stronger sustained outcomes.

DarioHealth (DRIO) reported Q1 2025 financial results with revenue of $6.75 million, up 17% year-over-year but down 11% sequentially. The company showed significant margin improvements with gross margin increasing to 57.5% from 42.2% in Q1 2024. Operating expenses decreased by 35% year-over-year to $13.3 million, while GAAP operating loss improved by 47% to $9.4 million. The company signed 14 new clients year-to-date, including health plans and employers, bringing total client count to 97. Dario expanded its platform through strategic partnerships for GLP-1 prescribing, behavioral health, and cardiometabolic support. The company completed an equity raise and debt refinancing, extending its runway to 2028, and remains on track to achieve operational cash flow breakeven by end of 2025.